Van Cutsem, E. http://orcid.org/0000-0002-6372-1230
Danielewicz, I.
Saunders, M. P.
Pfeiffer, P.
Argilés, G.
Borg, C.
Glynne-Jones, R. http://orcid.org/0000-0002-6742-222X
Punt, C. J. A.
Van de Wouw, A. J.
Fedyanin, M.
Stroyakovskiy, D.
Kroening, H.
Garcia-Alfonso, P.
Wasan, H. http://orcid.org/0000-0002-6268-2030
Falcone, A.
Fougeray, R.
Egorov, A.
Amellal, N.
Moiseyenko, V.
Funding for this research was provided by:
Servier
Taiho Pharmaceutical
Article History
Received: 28 July 2021
Revised: 21 January 2022
Accepted: 2 February 2022
First Online: 19 April 2022
Competing interests
: EVC has received research funding from Amgen, Bayer, Boehringer Ingelheim, Celgene, Ipsen, Lilly, Merck KGaA, MSD, Novartis, Roche, Sanofi, and Servier and has attended advisory boards for Array, Astellas, AstraZeneca, Bayer, Beigene, Biocartis, Bristol-Myers Squibb, Celgene, Daiichi, Halozyme, GS, Incyte, Ipsen, Lilly, Merck KGaA, MSD, Novartis, Pierre-Fabre, Roche, Servier and Taiho. ID has received research funding from AstraZeneca Pharma (Poland), Bayer, Bristol-Myers Squibb, Celgene, Eli Lilly, Immutep, Janssen-Cilag, Merck, MorphoSys, Novartis, Regeneron Pharmaceuticals, Roche, Servier and Tesaro. MPS has attended advisory boards and chaired meetings for Roche, Merck KGaA, Servier, Amgen, Sanofi and Eisai. PP has received research funding from Amgen, Celgene, Lilly, Merck KGaA, Roche, Taiho, Nordic Drugs and Servier. GA has received research funding from Servier and Bayer; has attended advisory boards for Servier, Bayer, Amgen, Sanofi, Merck Serono, Bristol-Myers Squibb and Roche and has received travel expenses and accommodation from Servier, Bayer, Amgen and Roche. CB has attended advisory boards for Roche, Servier and Sanofi and has received a research grant from Roche. RG-J has received research funding from Servier. CJAP has acted in an advisory role for Servier. AJVdW, MF, DS and HK have received research funding from Servier. PG-A has attended advisory boards and chaired meetings for Roche, Merck KGaA, Amgen, Sanofi, Lilly and Servier. HW has received honoraria, attended advisory boards and received travel grants and/or speaker fees from Bayer, Bristol-Myers Squibb, Lilly, Roche, Pfizer, Biotheranostics, Servier, Merck KGaA, Sirtex Medical, Sanofi-Aventis, Celgene and Array; has received research funding from Sirtex Medical, Merck Serono, Pfizer and Merck & Co (MSD) and has received charitable funds/grants from Cancer Research UK, Medical Research Council, National Institute for Health Research (NIHR) and the CUP Foundation. AF has received compensation for participation in advisory boards and research grants to his institution from Amgen, Bayer, Merck KGaA, MSD, Roche, Lilly, Servier and Bristol-Myers Squibb. AE, RF and NA are employees of Servier. V.M. has received research funding from Servier, BMS, MSD, Roche, Biocade, Sanofi and AstraZeneca.
: The study protocol was reviewed and approved by the Institutional Review Board at each participating centre, and was performed in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. All patients provided written informed consent to participate.
: Not applicable.